newsfilter
← Latest News
Business Wire·

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and